The multi-antigen panels and gating strategies currently employed at MD Anderson for the detection of BPDCN were recently described in detail and include the markers CD4, CD33, CD45, CD56, CD64, CD123, CD303, and HLA-DR. The gene discussed is NCAM1; the disease is CD4+/CD56+ hematodermic neoplasm.